A drug and exercise combo takes aim at the dangers of prolonged sitting in kidney disease

NCT ID NCT05173714

Disease control Sponsor: Srinvasan Beddhu Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This study tests whether adding guided resistance training and the medication semaglutide can help people with chronic kidney disease stick to a program that replaces one hour of sitting per day with light walking. The goal is to reduce sedentary time, which is linked to worse kidney function and higher risks of diabetes and heart disease. Participants will be followed for a year to see if these additions improve adherence and increase daily steps.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: semaglutide and guided resistance training
What this could lead to: If successful, this approach could offer a practical way to reduce sedentary behavior and improve physical function in people with chronic kidney disease.
What could go wrong: This is a mid-stage trial, so results may not be definitive. Semaglutide can cause gastrointestinal side effects, and the behavioral intervention may not sustain long-term adherence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 156 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2021

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2 * Able to perform resistance training * Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop Exclusion Criteria: * Type 1 Diabetes * History of gastroparesis or paralytic ileus * At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer * Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma. * Previous bariatric surgery * Medical condition likely to limit survival to less than 1 year * Anticipated start of dialysis or kidney transplantation within 6 months * Any factors judged by the investigator or study team to likely limit adherence to interventions * Vulnerable populations- pregnant or incarcerated * Enrolled in interventional trials using drugs or devices * Not able to undergo informed consent * Recent hospitalizations or major interventional procedures done within the past 60 days * Known or suspected hypersensitivity to tegaderm * Use of any GLP-1 receptor agonist within 30 days prior to screening * Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure * Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system) * Presence of metastatic cancer * Current use of mobility aid(s) * Living in the same household of a participant already enrolled in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney diseases Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

2 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

A drug and exercise combo takes aim at the dangers of prolonged sitting in kidney disease

What the study statuses mean